1. Home
  2. BBW vs CBIO Comparison

BBW vs CBIO Comparison

Compare BBW & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Build-A-Bear Workshop Inc.

BBW

Build-A-Bear Workshop Inc.

HOLD

Current Price

$25.16

Market Cap

473.7M

ML Signal

HOLD

Logo Crescent Biopharma Inc.

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$13.47

Market Cap

488.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBW
CBIO
Founded
1997
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
473.7M
488.1M
IPO Year
2004
2013

Fundamental Metrics

Financial Performance
Metric
BBW
CBIO
Price
$25.16
$13.47
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
★ $45.00
$31.50
AVG Volume (30 Days)
286.8K
★ 305.5K
Earning Date
12-03-2026
11-09-2026
Dividend Yield
★ 3.75%
N/A
EPS Growth
★ 5.00
N/A
EPS
★ 2.16
N/A
Revenue
★ $357,866,000.00
$18,500.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.33
$177.36
P/E Ratio
$11.39
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$23.19
$8.72
52 Week High
$72.19
$27.41

Technical Indicators

Market Signals
Indicator
BBW
CBIO
Relative Strength Index (RSI) 48.37 44.54
Support Level $24.29 $10.25
Resistance Level $26.40 $13.54
Average True Range (ATR) 1.01 0.98
MACD 0.19 0.17
Stochastic Oscillator 65.68 45.14

Price Performance

Historical Comparison
BBW
CBIO

About BBW Build-A-Bear Workshop Inc.

Build-A-Bear Workshop Inc is a U.S.-based specialty retailer of customized stuffed animals and related products. The company operates through three segments: Direct-to-consumer segment with key revenue, includes the operating activities of corporately-managed locations and other retail delivery operations in the U.S., Canada, U.K., Ireland, and two e-commerce sites, the international franchising segment includes royalties and product and fixture sales from other international operations under franchise agreements, and the commercial segment includes the transactions with other businesses, mainly comprised of licensing the intellectual properties for third-party use and wholesale activities.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: